Vertex: Buy At Ultracheap Multiples, Product Is Safe From AI

Vertex, Inc. is rated a Buy due to steady growth, margin expansion, recurring revenue, and high retention. Learn more about ...

Vertex Pharmaceuticals Stock: Is The Bull Run Over (Rating Downgrade)

Vertex Pharmaceuticals Incorporated faces slowing Trikafta/Kaftrio sales and a stock-price divergence with peers. Click for this VRTX earnings update.
The Motley Fool

Where Will Vertex Pharmaceuticals Be in 5 Years

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...
VentureBeat

Google launches Vertex AI, a fully managed cloud AI service

During a virtual keynote at Google I/O 2021, Google’s developer conference, Google announced the launch in general availability of Vertex AI, a managed AI platform. It’s designed to help companies to ...
Hosted on MSN

Vertex’s Journavx successor culled after falling short in Phase II trial

US-based Vertex Pharmaceuticals has axed plans to progress its acute pain drug, VX-993, into pivotal development after disappointing Phase II topline results. The NaV1.8 pain signal inhibitor, which ...